Myasthenic crisis in COVID-19

• Myasthenic crises is a potentially severe complication of COVID-19. • Hydroxychloroquine can aggravate myasthenia crises. • IVIg is a potential treatment for both Myasthenic crises and COVID-19. • IVIg treatment may cause thrombosis in susceptible patients.

Detalles Bibliográficos
Autores principales: Delly, Fadi, Syed, Maryam J., Lisak, Robert P., Zutshi, Deepti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200364/
https://www.ncbi.nlm.nih.gov/pubmed/32413767
http://dx.doi.org/10.1016/j.jns.2020.116888
_version_ 1783529318052265984
author Delly, Fadi
Syed, Maryam J.
Lisak, Robert P.
Zutshi, Deepti
author_facet Delly, Fadi
Syed, Maryam J.
Lisak, Robert P.
Zutshi, Deepti
author_sort Delly, Fadi
collection PubMed
description • Myasthenic crises is a potentially severe complication of COVID-19. • Hydroxychloroquine can aggravate myasthenia crises. • IVIg is a potential treatment for both Myasthenic crises and COVID-19. • IVIg treatment may cause thrombosis in susceptible patients.
format Online
Article
Text
id pubmed-7200364
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-72003642020-05-06 Myasthenic crisis in COVID-19 Delly, Fadi Syed, Maryam J. Lisak, Robert P. Zutshi, Deepti J Neurol Sci Letter to the Editor • Myasthenic crises is a potentially severe complication of COVID-19. • Hydroxychloroquine can aggravate myasthenia crises. • IVIg is a potential treatment for both Myasthenic crises and COVID-19. • IVIg treatment may cause thrombosis in susceptible patients. Elsevier B.V. 2020-07-15 2020-05-06 /pmc/articles/PMC7200364/ /pubmed/32413767 http://dx.doi.org/10.1016/j.jns.2020.116888 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Delly, Fadi
Syed, Maryam J.
Lisak, Robert P.
Zutshi, Deepti
Myasthenic crisis in COVID-19
title Myasthenic crisis in COVID-19
title_full Myasthenic crisis in COVID-19
title_fullStr Myasthenic crisis in COVID-19
title_full_unstemmed Myasthenic crisis in COVID-19
title_short Myasthenic crisis in COVID-19
title_sort myasthenic crisis in covid-19
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200364/
https://www.ncbi.nlm.nih.gov/pubmed/32413767
http://dx.doi.org/10.1016/j.jns.2020.116888
work_keys_str_mv AT dellyfadi myastheniccrisisincovid19
AT syedmaryamj myastheniccrisisincovid19
AT lisakrobertp myastheniccrisisincovid19
AT zutshideepti myastheniccrisisincovid19

Ejemplares similares